Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CohBar Inc CWBR

Healthcare Biotechnology
CohBar, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting chronic and age-related diseases. Its processes of identifying nucleic acid sequences encoding native peptides in the mitochondrial genome, developing and optimizing novel analogs of these natural mitochondrial derived peptides (MDPs) and developing and conducting screens to... see more

Recent & Breaking News (GREY:CWBR)

CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021

GlobeNewswire October 13, 2021

CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

GlobeNewswire October 5, 2021

CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

GlobeNewswire September 15, 2021

CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)

GlobeNewswire September 8, 2021

CohBar to Present at Upcoming Investor Conferences

GlobeNewswire September 2, 2021

CohBar Appoints Carol Nast to Its Board of Directors

GlobeNewswire August 16, 2021

CohBar Reports Second Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire August 10, 2021

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

GlobeNewswire August 10, 2021

CohBar to Announce 2021 Second Quarter Financial Results and Provide Business Update on August 10, 2021

GlobeNewswire August 4, 2021

CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

GlobeNewswire July 14, 2021

CohBar to Present at the BIO 2021 Digital Conference

GlobeNewswire June 10, 2021

CohBar Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire May 17, 2021

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

GlobeNewswire May 3, 2021

CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

GlobeNewswire April 27, 2021

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

GlobeNewswire April 21, 2021

CohBar to Present at the Mitochondria-Targeted Drug Development Summit

GlobeNewswire April 14, 2021

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire March 30, 2021

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

GlobeNewswire March 29, 2021

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

GlobeNewswire March 16, 2021

CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases

GlobeNewswire March 16, 2021